| P2093 | author name string | Yang Yang | |
| | Qiquan Sun | |
| P2860 | cites work | Proteasome inhibitor-based therapy for antibody-mediated rejection | Q26830410 |
| | The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 |
| | A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection | Q32041368 |
| | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| | The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation | Q33392607 |
| | Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports | Q33404327 |
| | Diagnosis and prevention of chronic kidney allograft loss | Q34224452 |
| | Picking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluation | Q34423734 |
| | Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection | Q34534855 |
| | Kidney transplants, antibodies and rejection: is C4d a magic marker? | Q35556559 |
| | Chronic renal allograft dysfunction | Q36240051 |
| | Antibody-Mediated Lung Transplant Rejection | Q36243057 |
| | Antibody-mediated organ-allograft rejection | Q36263023 |
| | Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection | Q36317528 |
| | Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation | Q36666906 |
| | Antibody-mediated renal allograft rejection: diagnosis and pathogenesis | Q36759900 |
| | The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 |
| | Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft | Q84145395 |
| | Antibody-mediated rejection--an ounce of prevention is worth a pound of cure | Q84284651 |
| | Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema | Q84666244 |
| | Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 |
| | Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant | Q85570146 |
| | Microcirculation lesions alone are not reliable for identifying antibody-mediated rejection | Q86961635 |
| | Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. | Q37058039 |
| | Transplant glomerulopathy | Q37092282 |
| | Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection | Q37441972 |
| | The pathogenesis and treatment of chronic allograft nephropathy | Q37563986 |
| | Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection | Q37654098 |
| | Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection | Q37930193 |
| | Antibody-mediated rejection after intestinal transplantation | Q38000008 |
| | Antibody-mediated rejection in the liver allograft | Q38008547 |
| | Prevention of antibody-mediated kidney transplant rejection | Q38010231 |
| | Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 |
| | Pathology of C4d-negative antibody-mediated rejection in renal allografts | Q38071202 |
| | Incidence and impact of de novo donor-specific alloantibody in primary renal allografts | Q39472834 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Late and early C4d-positive acute rejection: different clinico-histopathological subentities in renal transplantation. | Q40477268 |
| | Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection | Q43150813 |
| | Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection | Q43685024 |
| | C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. | Q43775992 |
| | Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 |
| | Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody | Q44193180 |
| | A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 |
| | Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 |
| | Early versus late acute antibody-mediated rejection in renal transplant recipients. | Q46415040 |
| | Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 |
| | Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients | Q46900024 |
| | The pathogenesis of acute allograft dysfunction in desensitized renal transplant recipients | Q47279030 |
| | National conference to assess antibody-mediated rejection in solid organ transplantation | Q47347260 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. | Q48005087 |
| | Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression. | Q50582511 |
| | Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. | Q50654391 |
| | A survey of current practice for antibody-mediated rejection in heart transplantation. | Q51256229 |
| | Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. | Q51789761 |
| | Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. | Q53244973 |
| | Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 |
| | Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. | Q53388675 |
| | Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 |
| | Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation | Q77736829 |
| | All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies | Q78534560 |
| | Successful rescue of refractory, severe antibody mediated rejection with splenectomy | Q79552624 |
| | Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') | Q79921621 |
| | Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil | Q80252616 |
| | Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 |
| | Usefulness of splenectomy for chronic active antibody-mediated rejection after renal transplantation | Q80678156 |
| | Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 |
| | Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients | Q82588311 |
| | C4d immunostaining in acute humoral rejection after ABO blood group-incompatible liver transplantation | Q82650120 |
| | Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls | Q84033585 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 859761 | |
| P577 | publication date | 2013-01-01 | |
| | 2013-10-08 | |
| P1433 | published in | Clinical and Developmental Immunology | Q15754140 |
| P1476 | title | Late and chronic antibody-mediated rejection: main barrier to long term graft survival | |
| P478 | volume | 2013 | |